Last Price$205.7(1.0%)
Market Cap$151.3B
LTM Research & Development Expenses (R&D)
$1,584.0M
YoY Growth
+5.4%
3Y CAGR
-3.1%
5Y CAGR
+4.9%
Stock quality & Intrinsic value
6/10
18.8% overvalued
Danaher Corporation Research & Development Expenses (R&D)
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & Development Expenses (R&D) | $0.0 | $0.0 | $601.4M | $725.4M | $632.7M | $809.5M | $1,018.5M | $1,137.9M | $1,249.9M | $1,314.2M | $1,239.1M | $975.1M | $1,128.8M | $1,231.2M | $1,126.0M | $1,348.0M | $1,742.0M | $1,745.0M | $1,503.0M | $1,584.0M |
Overvalued or undervalued?
Check the intrinsic value for DHR
and see if it's the right time to invest.
Danaher Corporation (DHR) Research & Development Expenses (R&D) comparison analysis
General
LTM Research & Development Expenses (R&D)
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Danaher CorporationDHR
$1,584.0M
5.4%
(3.1%)
4.9%
Median Peer Set
$204.6M
1.1%
0.3%
5.4%
Thermo Fisher Scientific Inc.TMO
$1,390.0M
4.0%
(0.4%)
6.7%
Illumina, Inc.ILMN
$1,172.0M
(12.7%)
(0.4%)
12.6%
Agilent Technologies, Inc.A
$464.0M
(2.9%)
0.7%
2.7%
Natera, Inc.NTRA
$357.6M
9.8%
16.7%
48.7%
IDEXX Laboratories, Inc.IDXX
$219.8M
15.1%
10.9%
10.5%
Mettler-Toledo International Inc.MTD
$189.4M
2.2%
3.7%
5.6%
Waters CorporationWAT
$183.0M
4.6%
2.8%
5.1%
IQVIA Holdings Inc.IQV
$0.0
N/A
N/A
N/A
Laboratory Corporation of America HoldingsLH
$0.0
(100.0%)
N/A
N/A
Quest Diagnostics IncorporatedDGX
$0.0
N/A
N/A
N/A
DHR key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 7,984.7 15.9% | 9,596.4 20.2% | 11,025.9 14.9% | 12,697.5 15.2% | 11,184.9 (11.9%) | 13,202.6 18.0% | 16,090.5 21.9% | 18,260.4 13.5% | 19,118.0 4.7% | 19,913.8 4.2% | 20,563.1 3.3% | 16,882.4 (17.9%) | 18,329.7 8.6% | 19,893.0 8.5% | 17,911.1 (10.0%) | 22,284.0 24.4% | 29,453.0 32.2% | 31,471.0 6.9% | 23,890.0 (24.1%) | 23,875.0 (0.1%) |
| Cost of Goods Sold (COGS) | 4,539.7 | 5,353.0 | 5,985.0 | 6,757.3 | 5,904.7 | 6,575.8 | 7,913.9 | 8,846.1 | 9,160.4 | 9,471.3 | 9,800.6 | 7,547.8 | 8,137.2 | 8,785.9 | 7,927.4 | 9,809.0 | 11,501.0 | 12,522.0 | 9,856.0 | 9,669.0 |
% margin | 3,445.0 43.1% | 4,243.4 44.2% | 5,040.9 45.7% | 5,940.2 46.8% | 5,280.2 47.2% | 6,626.8 50.2% | 8,176.7 50.8% | 9,414.3 51.6% | 9,957.6 52.1% | 10,442.5 52.4% | 10,762.5 52.3% | 9,334.6 55.3% | 10,192.5 55.6% | 11,107.1 55.8% | 9,983.7 55.7% | 12,475.0 56.0% | 17,952.0 61.0% | 18,949.0 60.2% | 14,034.0 58.7% | 14,206.0 59.5% |
| Operating Expenses | 2,180.3 | 2,725.4 | 3,300.2 | 4,070.7 | 3,737.7 | 4,483.2 | 5,559.4 | 6,319.1 | 6,682.7 | 7,011.2 | 7,293.4 | 6,583.7 | 7,171.3 | 7,703.3 | 6,714.3 | 8,244.0 | 10,487.0 | 10,261.0 | 8,832.0 | 9,343.0 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 601.4 | 725.4 | 632.7 | 809.5 | 1,018.5 | 1,137.9 | 1,249.9 | 1,314.2 | 1,239.1 | 975.1 | 1,128.8 | 1,231.2 | 1,126.0 | 1,348.0 | 1,742.0 | 1,745.0 | 1,503.0 | 1,584.0 |
| Selling, General & Administrative Expenses (SG&A) | 2,175.8 | 2,741.8 | 2,713.1 | 3,345.3 | 3,190.2 | 3,673.7 | 4,607.7 | 5,181.2 | 5,432.8 | 5,697.0 | 6,054.3 | 5,608.6 | 6,042.5 | 6,472.1 | 5,588.3 | 6,896.0 | 8,198.0 | 8,516.0 | 7,252.0 | 7,759.0 |
% margin | 1,264.7 15.8% | 1,518.0 15.8% | 1,740.7 15.8% | 1,869.5 14.7% | 1,542.5 13.8% | 2,166.4 16.4% | 2,617.2 16.3% | 3,165.1 17.3% | 3,274.9 17.1% | 3,431.3 17.2% | 3,469.1 16.9% | 2,750.9 16.3% | 3,021.2 16.5% | 3,403.8 17.1% | 3,269.4 18.3% | 4,231.0 19.0% | 7,465.0 25.3% | 8,688.0 27.6% | 5,202.0 21.8% | 4,863.0 20.4% |
| Interest Income | 0.0 | 0.0 | 6.1 | 10.0 | 5.0 | 6.1 | 5.1 | 3.2 | 5.7 | 16.7 | 5.3 | 0.2 | 7.5 | 9.2 | 139.0 | 71.0 | 11.0 | 41.0 | 303.0 | 117.0 |
| Interest Expense | 0.0 | 0.0 | 109.7 | 130.2 | 122.7 | 120.8 | 141.6 | 157.5 | 145.9 | 122.7 | 162.8 | 184.4 | 162.7 | 157.4 | 108.6 | 275.0 | 238.0 | 211.0 | 286.0 | 278.0 |
| Pre-tax Income | 1,234.4 | 1,446.2 | 1,637.1 | 1,749.3 | 1,424.9 | 2,342.7 | 2,447.8 | 3,010.8 | 3,566.0 | 3,481.8 | 3,324.0 | 2,611.3 | 2,938.8 | 3,292.8 | 3,305.3 | 4,495.0 | 7,598.0 | 8,292.0 | 5,044.0 | 4,646.0 |
% effective tax rate | 336.6 27.3% | 324.1 22.4% | 423.1 25.8% | 431.7 24.7% | 273.2 19.2% | 549.7 23.5% | 512.6 20.9% | 711.5 23.6% | 871.0 24.4% | 883.4 25.4% | 725.3 21.8% | 457.9 17.5% | 469.0 16.0% | 641.9 19.5% | 873.0 26.4% | 849.0 18.9% | 1,251.0 16.5% | 1,083.0 13.1% | 823.0 16.3% | 747.0 16.1% |
% margin | 897.8 11.2% | 1,122.0 11.7% | 1,369.9 12.4% | 1,317.6 10.4% | 1,151.7 10.3% | 1,793.0 13.6% | 2,172.3 13.5% | 2,392.2 13.1% | 2,695.0 14.1% | 2,598.4 13.0% | 3,357.4 16.3% | 2,553.7 15.1% | 2,492.1 13.6% | 2,650.9 13.3% | 3,008.2 16.8% | 3,646.0 16.4% | 6,433.0 21.8% | 7,209.0 22.9% | 4,764.0 19.9% | 3,899.0 16.3% |
| EPS | 1.46 | 1.82 | 2.20 | 2.07 | 1.80 | 2.74 | 3.21 | 3.45 | 3.87 | 3.70 | 4.81 | 3.69 | 3.58 | 3.78 | 3.48 | 4.97 | 8.77 | 9.80 | 6.44 | 5.29 |
| Diluted EPS | 1.38 | 1.74 | 2.10 | 1.98 | 1.73 | 2.64 | 3.11 | 3.36 | 3.80 | 3.63 | 4.74 | 3.65 | 3.53 | 3.73 | 3.43 | 4.89 | 8.61 | 9.64 | 6.38 | 5.29 |
% margin | 1,456.3 18.2% | 1,743.2 18.2% | 2,015.3 18.3% | 2,218.8 17.5% | 1,889.1 16.9% | 2,860.6 21.7% | 3,224.4 20.0% | 4,008.1 21.9% | 4,606.9 24.1% | 4,543.0 22.8% | 3,207.5 15.6% | 4,031.7 23.9% | 4,339.8 23.7% | 4,276.5 21.5% | 4,603.4 25.7% | 6,590.0 29.6% | 10,007.0 34.0% | 9,712.0 30.9% | 7,499.0 31.4% | 4,863.0 20.4% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Danaher Corporation's Research & Development Expenses (R&D)?
As of today, Danaher Corporation's last 12-month Research & Development Expenses (R&D) is $1,584.0M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Danaher Corporation's Research & Development Expenses (R&D) growth rate?
Over the last year, Danaher Corporation's Research & Development Expenses (R&D) growth was 5.4%. The average annual Research & Development Expenses (R&D) growth rates for Danaher Corporation have been 0.8% over the past three years, 4.9% over the past five years.
3) Is Danaher Corporation's Research & Development Expenses (R&D) growth rate Good?
Over the last year, Danaher Corporation's Research & Development Expenses (R&D) growth was 5.4%, which is higher than industry growth of (0.3%). It indicates that Danaher Corporation's Research & Development Expenses (R&D) growth is Bad.